At study entry, 40 percent of the entire study population acquired measurable disease and could be assessed for a target response according to RECIST guidelines; the response price was 12 percent in the olaparib group, as compared with 4 percent in the placebo group . During the data-cutoff stage for progression-free survival, too few deaths had happened for a survival analysis to be performed. However, at the interim evaluation of overall survival , 101 individuals had died: 52 in the olaparib group and 49 in the placebo group. No factor in general survival was noticed . The median overall survival was related in the two study organizations .Sadayappan stated stem cell therapy could be a feasible treatment. Stem cells will be extracted from a patient’s center, engineered to replace the mutated gene with a healthy gene genetically, and after that injected back the patient’s heart. But such stem cell therapy is not tested. Nor will there be a commercial test for the gene, Sadayappan stated. But Sadayappan and other researchers are researching how cMyBP-C functions actively. And improved understanding of this crucial proteins, Sadayappan said, could lead to new medications to take care of heart failure. Next year may be the 40th anniversary of the discovery of cMyBP-C, and researchers still have much to learn on the subject of the function of the protein in the heart.